Ophthalmology

Technology helps physicians understand normal and abnormal macular anatomy

Key is to recognize usual patterns for systemic and topical medications

Transient sensory-motor abnormalities are often common

Injections and implants continue to create further positive outcomes for patients.

Novel option demonstrates stable to improved visual acuity and retinal thickness

Minimizing clinic visits, maximizing use of imaging modalities are key

Options for physicians are increasing in availability, with fewer costs and travel burdens for patients

Ophthalmologist provides patient counseling pearls for selected retinal dystrophies

Novel gene therapy/medical device combo sheds light on retina in RP

Three sessions cover the range from clinical updates for imaging to emerging therapies for non-exudative AMD.

John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.

From patient care and treating glaucoma to the ongoing pandemic, ophthalmologists share the most pressing thoughts of concern leaving them awake at night.

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

During AAO 2020, Neal H. Shorstein, MD, explains how physicians at Kaiser Permanente have a streamlined regimen using a prophylactic drop-free drug before cataract surgery for more than a decade.

Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.

Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).

During AAO 2020, Kathleeen B. Digre, MD, details how a headache in conjunction with visual loss is a scenario that requires an in-depth examination, including evaluation of the visual fields, pupils, and fundus to gather clues to the diagnosis.

Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.

Ram Liebenthal, U.S. general manager for Heidelberg Engineering, discusses how the company continues to invest in the Spectralis platform in terms of hardware and software improvements.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Ted Leng, MD, MS, Byers Eye Institute at Stanford, and medical advisor for Verana Health, talks about data insights for retinal surgeons. Steven D. Schwartz, MD, Stein Eye Institute, UCLA, highlights his AAO presentation, “New Insight into Real-World U.S. Injection Data."

At AAO 2020, Fernando Arevalo, MD, PhD, details the use of anti-VEGF therapy for the treatment of retinal arteriolar macroaneurysms that are near the fovea.